Minimally Invasive In Vivo Real-Time Identification of Human Astrocytoma with Sulforhodamine 101
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Abstract
Background: Specific brain tumor diagnoses depend on histopathologic
interrogation of biopsies. Though helpful, current histopathological
techniques lack the speed and specificity to be effective intraoperative
diagnostic tools. Here we show that in vivo imaging of rodents implanted
with human astrocytoma rapidly labeled with the physiological fluorophore
sulforhodamine 101 (SR101) can immediately identify an astrocytic tumor
from normal brain tissue.
Methods: Nude rats (n= 4) were stereotactically implanted with cultured
human astrocytoma cells unilaterally. Five-weeks post implantation, rats
were deeply anesthetized and underwent minimal bilateral craniotomies.
SR101 (n=4) was applied subcortically through each craniotomy. An
0.85mm diameter fiber optic imaging bundle was attached to a FluoView
1000 confocal microscope, then passed through each craniotomy. Images
were collected from the surface to a depth of five millimeters. Rodent
brains were then extracted for ex vivo imaging. Fixed tissue was imaged
following topical application of acridine orange (AO).
Results: Areas with tumor burden were immediately identified on the
hemisphere implanted with tumor cells with SR101 labeling. Minimal
SR101 labeling was appreciated within hemispheres contralateral to tumor
implantation. Counterstaining with AO verified SR101 localized to areas
of hypercellular astrocytoma.
Conclusion: SR101 rapidly and selectively labeled regions of human
astrocytoma in rodent orthotopic xenografts. Coupled with in vivo imaging,
SR101 shows utility for producing biopsy-free specific histological
diagnoses. Clinical application of SR101 may provide immediate and
specific intraoperative identification of astrocytic brain tumors.
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Intracranial implantation: Nude rats (n=4) were anesthetized and
placed in a small animal stereotactic headframe. A small incision was
made to expose bregma. A burr hole was made 3.5 mm lateral to
bregma. Human astrocytoma cells were infused at a depth of 4.5 mm
below the surface of the brain, the burr hole was covered with bone
wax and skin incision was sutured.
Craniotomy: Five-weeks following tumor implantation, animals were
anesthetized and placed in a small animal stereotactic headframe. A
3mm diameter burr hole was made over the tumor implantation site
and over contralateral normal brain.

Figure 1. Minimally invasive imaging. Our microendoscope constructed from a 0.85mm diameter fiber optic
bundle has a smaller cross-sectional area than a Camino ICP monitor (1.30mm) and ventricular catheter
(3.00mm) which are routinely placed by neurosurgeons at bedside. The microendoscope permitted immediate
ex vivo imaging of tissue biopsies and in vivo imaging through a miniature craniotomy.
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Tumor labeling: To specifically label astrocytoma cells, twelve
microliters of 50µM SR101 was injected at a depth of 3mm from the
brain surface 20 minutes prior to imaging. Acridine orange (5mM) was
applied topically to ex vivo tissue to nonspecifically label cells in the
field of view for histological tumor verification.
Imaging: We constructed our fiber optic microendoscope by coupling
a 0.85mm diameter silica-based coherent fiber bundle to an Olympus
Fluoview 1000 confocal microscope. The pinhole was set to sample at
one Airy unit and framesize set to image at Nyquist. AO and SR101
were imaged sequentially with 488nm and 560nm excitation,
respectively. Imaging began at the brain surface and stepwise with
1mm increments to a depth of 5mm. Images were processed with
linear functions utilizing NIH ImageJ.

Introduction
In neuro-oncology, specific tumor diagnoses are critical for
development of treatment plans. Though multiple noninvasive
imaging modalities exist, such as MRI, PET and CT scan, direct
tumor sampling is often required for a definitive diagnosis.
Sampling is typically achieved with either open biopsy or
stereotactic needle biopsy. In open biopsy, a craniotomy is
performed to directly visualize and biopsy a tumor sample. With
fine needle biopsy (FNB), tumor is sampled through a small bur
hole. Though less invasive, FNB suffers from greater missampling
rates leading to acquisition of nondiagnositic tissue.
Intraoperatively, frozen sections help determine if sampled tissue
contains tumor, necrosis, or normal brain. However, definitive tumor
diagnoses require specific stains which take several days to
acquire. During this time, treatment plans for patients are delayed,
as different pathologies require different treatment plans. Such is
the case with astrocytoma compared to CNS lymphoma. These
pathologies can appear similar with both noninvasive imaging and
on frozen section, yet astrocytoma is best treated with surgical
resection, and lymphoma is best treated nonsurgically with
chemoradiation.
We propose developing a minimally invasive technique for
generating rapid and specific in vivo intraoperative
histopathologic diagnoses of astrocytic brain tumors by
utilizing a physiologic fluorophore that discriminates
astrocytoma from lymphoma, sulforhodamine 101.
The
development of fiber optic fluorescent imaging devices coupled with
rapid and specific fluorescent biomarkers have had widespread
utility in basic neuroscience. In this project, we model and
investigate clinical application of these techniques on rodent
orthotopic xenographs of human astrocytoma. We hypothesize in
vivo imaging with a miniaturized fluorescent microendoscope will
provide real-time tumor sampling and feedback which will allow
immediate intraoperative identification of these malignant brain
tumors.

Summary and Conclusions

Figure 2. Ex vivo Imaging with acridine orange differentiates tumor from normal brain. Acridine orange
immediately and nonspecifically stained cells within the field of view. Tumor regions were hypercellular
compared to normal brain. Hypercellular and hypocellar tissue regions were visualized at the tumor margin.
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In vivo imaging with SR101 provides rapid and
specific identification of human astrocytic
tumors in rodent orthotopic xenographs.
SR101 is a robust live-cell imaging physiologic
fluorophore routinely utilized to specifically
identify astrocytic cells in live tissue. SR101’s
strong specificity to astrocytoma cells in fresh
tissue has been previously reported. Coupled
with a minimally invasive fluorescent
microendoscope, we show SR101 may have
utility for providing immediate biopsy-free in
vivo histopathological diagnoses.
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Figure 3. In vivo Imaging with sulforhodamine 101 specifically labels astrocytoma.
Normal brain lacked areas with strong SR101 labeling. Regions with strong SR101 positivity were observed
through the craniotomy ipsilateral to tumor implantation. SR101 labeling permitted real-time in vivo visualization
of tumor margins (arrows) and regions of frank tumor. Scale bar equals 20µm.
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